Sato-Akushichi Miki, Ono Shinji, Taneda Tatsuro, Klose Gerd, Sasamori Asuka, Song Youngseok
Department of Ophthalmology, Asahikawa Medical University, Asahikawa 078-8510, Japan.
Sapporo Ohno Eye Clinic, Sapporo 065-0024, Japan.
Pharmaceuticals (Basel). 2022 Apr 15;15(4):483. doi: 10.3390/ph15040483.
This paper evaluates a one-year treatment outcome after full or reduced photodynamic therapy (PDT) and anti-vascular endothelial growth factor (VEGF) combination therapy for pachychoroid neovasculopathy (PNV). After the initial combination therapy, a total of 29 eyes from 29 patients (16 for full treatment and 13 for reduced treatment), exhibited reduced, central retinal thickness and central choroidal thickness, and the improvements were maintained for 1 year after the initial combination therapy. Twenty-two eyes (75.9%) required no additional treatments for 1 year. The recurrence rate was 31.3% in the full treatment and 15.4% in the reduced treatment, with no significant differences between them. One shot of anti-VEGF and full or reduced PDT combination therapy had similar efficacy in treating PNV. Further prospective, large-scale, and long-term studies are required to determine a better treatment for PNV.
本文评估了全剂量或减量光动力疗法(PDT)联合抗血管内皮生长因子(VEGF)治疗厚脉络膜新生血管病变(PNV)一年后的治疗效果。初始联合治疗后,29例患者的29只眼(16例接受全剂量治疗,13例接受减量治疗),视网膜中央厚度和脉络膜中央厚度均减小,且在初始联合治疗后1年内这些改善情况得以维持。22只眼(75.9%)在1年内无需额外治疗。全剂量治疗的复发率为31.3%,减量治疗的复发率为15.4%,两者之间无显著差异。单次抗VEGF联合全剂量或减量PDT治疗PNV具有相似的疗效。需要进一步开展前瞻性、大规模和长期研究,以确定针对PNV的更佳治疗方案。